TRUQAP (capivasertib)
HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED ADVANCED BREAST CANCER·+1
AstraZeneca Pharmaceuticals
Indication
PTEN-deficient metastatic prostate cancer
PTEN-deficient metastatic prostate cancer is an advanced, aggressive malignancy of the male reproductive tract in which neoplastic cells originating in the prostate gland have disseminated to distant sites, such as the regional lymph nodes, skeletal system, or visceral organs. Read more about PTEN-deficient metastatic prostate cancer
1 drugs 1 manufacturers
Drugs that treat it
Common PTEN-deficient metastatic prostate cancer therapies.
Filter & compare in the drug finder →Opens the drug finder with PTEN-deficient metastatic prostate cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPTEN-deficient metastatic prostate cancer is an advanced, aggressive malignancy of the male reproductive tract in which neoplastic cells originating in the prostate gland have disseminated to distant sites, such as the regional lymph nodes, skeletal system, or visceral organs.
The defining pathophysiologic hallmark is the genomic deletion, mutational inactivation, or loss of protein expression of the phosphatase and tensin homolog (PTEN) tumor suppressor gene.
Functionally, the absence of active PTEN lipid phosphatase leads to unrestrained hyperactivation of the intracellular PI3K-AKT-mTOR signaling cascade, driving sustained cellular proliferation, survival, and metabolic reprogramming.
Clinically, this biomarker-defined disease subset is characterized by accelerated progression, enhanced resistance to standard androgen-receptor-directed therapies, and poorer overall survival compared to PTEN-intact malignancies.
- nih.gov
PTEN-deficient metastatic prostate cancer is an advanced, aggressive malignancy of the male reproductive tract in which neoplastic cells originating in the prostate gland have disseminated to distant sites, such as the regional lymph nodes, skeletal system, or visceral organs The defining pathophysiologic hallmark is the genomic deletion, mutational inactivation, or loss of protein expression of the phosphatase and tensin homolog (PTEN) tumor suppressor gene Functionally, the absence of active P...
- nih.gov
PTEN-deficient metastatic prostate cancer is an advanced, aggressive malignancy of the male reproductive tract in which neoplastic cells originating in the prostate gland have disseminated to distant sites, such as the regional lymph nodes, skeletal system, or visceral organs Clinically, this biomarker-defined disease subset is characterized by accelerated progression, enhanced resistance to standard androgen-receptor-directed therapies, and poorer overall survival compared to PTEN-intact malign...
- uky.edu
PTEN-deficient metastatic prostate cancer is an advanced, aggressive malignancy of the male reproductive tract in which neoplastic cells originating in the prostate gland have disseminated to distant sites, such as the regional lymph nodes, skeletal system, or visceral organs
- nih.gov
The defining pathophysiologic hallmark is the genomic deletion, mutational inactivation, or loss of protein expression of the phosphatase and tensin homolog (PTEN) tumor suppressor gene Functionally, the absence of active PTEN lipid phosphatase leads to unrestrained hyperactivation of the intracellular PI3K-AKT-mTOR signaling cascade, driving sustained cellular proliferation, survival, and metabolic reprogramming Clinically, this biomarker-defined disease subset is characterized by accelerated p...
- survivornet.com
Clinically, this biomarker-defined disease subset is characterized by accelerated progression, enhanced resistance to standard androgen-receptor-directed therapies, and poorer overall survival compared to PTEN-intact malignancies
Personalize your experience
Follow PTEN-deficient metastatic prostate cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.